AU2001292846A1 - Biological markers for evaluating therapeutic treatment of inflammatory and autoimmune disorders - Google Patents

Biological markers for evaluating therapeutic treatment of inflammatory and autoimmune disorders

Info

Publication number
AU2001292846A1
AU2001292846A1 AU2001292846A AU9284601A AU2001292846A1 AU 2001292846 A1 AU2001292846 A1 AU 2001292846A1 AU 2001292846 A AU2001292846 A AU 2001292846A AU 9284601 A AU9284601 A AU 9284601A AU 2001292846 A1 AU2001292846 A1 AU 2001292846A1
Authority
AU
Australia
Prior art keywords
inflammatory
therapeutic treatment
autoimmune disorders
biological markers
evaluating therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001292846A
Inventor
Susan E. Alters
Karen L. Cheal
Aaron B. Kantor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alavita Pharmaceuticals Inc
Original Assignee
Surromed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Surromed Inc filed Critical Surromed Inc
Publication of AU2001292846A1 publication Critical patent/AU2001292846A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/5052—Cells of the immune system involving B-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
AU2001292846A 2000-09-20 2001-09-20 Biological markers for evaluating therapeutic treatment of inflammatory and autoimmune disorders Abandoned AU2001292846A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US23431300P 2000-09-20 2000-09-20
US60/234,313 2000-09-20
US23928100P 2000-10-10 2000-10-10
US60/239,281 2000-10-10
US24613700P 2000-11-06 2000-11-06
US60/246,137 2000-11-06
US30456301P 2001-07-10 2001-07-10
US60/304,563 2001-07-10
PCT/US2001/029392 WO2002033377A2 (en) 2000-09-20 2001-09-20 Biological markers for evaluating therapeutic treatment of inflammatory and autoimmune disorders

Publications (1)

Publication Number Publication Date
AU2001292846A1 true AU2001292846A1 (en) 2002-04-29

Family

ID=27499728

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001292846A Abandoned AU2001292846A1 (en) 2000-09-20 2001-09-20 Biological markers for evaluating therapeutic treatment of inflammatory and autoimmune disorders

Country Status (3)

Country Link
US (2) US6753135B2 (en)
AU (1) AU2001292846A1 (en)
WO (1) WO2002033377A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2443806A1 (en) 2000-04-14 2002-10-25 Metabolon, Inc. Methods for drug discovery, disease treatment, and diagnosis using metabolomics
US7329489B2 (en) 2000-04-14 2008-02-12 Matabolon, Inc. Methods for drug discovery, disease treatment, and diagnosis using metabolomics
US20100121360A9 (en) * 2000-12-20 2010-05-13 Fox Hollow Technologies, Inc Testing a patient population having a cardiovascular condition for drug efficacy
US20050170372A1 (en) * 2001-08-13 2005-08-04 Afeyan Noubar B. Methods and systems for profiling biological systems
IL160324A0 (en) * 2001-08-13 2004-07-25 Beyond Genomics Inc Method and system for profiling biological systems
US20030175713A1 (en) * 2002-02-15 2003-09-18 Clemens Sorg Method for diagnosis of inflammatory diseases using CALGRANULIN C
AU2003284894A1 (en) * 2002-10-24 2004-06-03 Oklahoma Medical Research Foundation An associative analysis of gene expression array data
US20040115647A1 (en) * 2002-12-12 2004-06-17 Paterson Thomas S. Apparatus and method for identifying biomarkers using a computer model
KR101260497B1 (en) * 2003-01-24 2013-09-12 엘란 파마슈티칼스, 인크. Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
EP1514945A1 (en) * 2003-09-09 2005-03-16 Warner-Lambert Company LLC CD38 as a molecular marker on macrophages for COPD, and as a target molecule for treatment of COPD
US20060051744A1 (en) * 2004-06-30 2006-03-09 Austin Kimberly M Feline infectious peritonitis (FIP) and systemic multi-organ coronavirus biomarkers and screening methods
EP1844156A2 (en) * 2004-09-24 2007-10-17 Vitrimark, Inc. Systems and methods of identifying biomarkers for subsequent screening and monitoring of diseases
AU2005314446A1 (en) * 2004-11-16 2006-06-15 Janssen Pharmaceutica N.V. Sphingosine kinase-1 mediates gene expression regulation of a monocyte chemoattractant protein-1 gene
US20110236902A1 (en) * 2004-12-13 2011-09-29 Tyco Healthcare Group Lp Testing a patient population having a cardiovascular condition for drug efficacy
US9220813B2 (en) * 2005-04-18 2015-12-29 Holy Cross Hospital, Inc. Cell therapy for limiting overzealous inflammatory reactions in tissue healing
US7794413B2 (en) * 2005-04-19 2010-09-14 Ev3, Inc. Libraries and data structures of materials removed by debulking catheters
DK1929297T3 (en) * 2005-09-29 2013-03-04 Caprion Proteomics Usa Llc Biomarkers for disseminated sclerosis and methods for its use
US8849577B2 (en) 2006-09-15 2014-09-30 Metabolon, Inc. Methods of identifying biochemical pathways
WO2011026081A1 (en) * 2009-08-31 2011-03-03 Florida Atlantic University Chitin-binding proteins as biomarkers
US20130195840A1 (en) * 2010-01-13 2013-08-01 Robert P. Kimberly Therapeutics and processes for treatment of immune disorders
US20140128282A1 (en) 2012-11-08 2014-05-08 Nestec Sa Immune function biomarkers
CN107076745A (en) * 2014-08-29 2017-08-18 贝克顿·迪金森公司 The method and composition that tuberculosis is evaluated is obtained in subject
WO2018015375A1 (en) 2016-07-20 2018-01-25 Westfälische Wilhelms-Universität Münster Complex-specific standardization of immunological methods for the quantification of s100a12

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874080A (en) 1994-03-03 1999-02-23 Genentech, Inc. Anti-IL-8 monoclonal antibodies for treatment of asthma
US5683983A (en) 1995-06-07 1997-11-04 Glaxo Group Limited Peptides and compounds that bind to the IL-5 receptor
US5908839A (en) 1995-08-24 1999-06-01 Magainin Pharmaceuticals, Inc. Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
IL141647A0 (en) * 2001-02-26 2002-03-10 Yeda Res & Dev Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus

Also Published As

Publication number Publication date
US6753135B2 (en) 2004-06-22
WO2002033377A3 (en) 2003-02-06
US20050002862A1 (en) 2005-01-06
WO2002033377A2 (en) 2002-04-25
US20020072484A1 (en) 2002-06-13

Similar Documents

Publication Publication Date Title
AU2001292846A1 (en) Biological markers for evaluating therapeutic treatment of inflammatory and autoimmune disorders
AU2001259758A1 (en) Interleukin-1 inhibitors in the treatment of diseases
AU2001275257A1 (en) Methods and devices for the treatment of urinary incontinence
IL153824A0 (en) Method and kit for diagnosis of diseases
AU2002352726A8 (en) Formulations and methods for treatment or amelioration of inflammatory conditions
WO2002086502A8 (en) Methods for the diagnosis and treatment of bone disorders
AU2002252373A1 (en) Methods and compositions for the treatment and/or diagnosis of neurological diseases and disorders
GB0007193D0 (en) Treatment of movrmrnt disorders
AU2003223579A1 (en) Combinations of cox-2 inhibitors and other agents for the treatment of parkinson's disease
AU2002239491A1 (en) Methods for the treatment of cancer and other diseases and methods of developing the same
AU2002320147A1 (en) Microdialysis probes and methods of use
HK1043348A1 (en) Brush-writing instruments for health and therapy
AU2003249645A8 (en) Methods for the identification of ikkalpha function and other genes useful for treatment of inflammatory diseases
AU2002353777A1 (en) Saliva-based methods for preventing and assessing the risk of diseases
AU2002237667A1 (en) Methods for the treatment and prevention of urinary stone disease
AU2002252976A1 (en) Hydrazones and their therapeutic use
IL158050A0 (en) Use of selective cox-2 inhibitors for the treatment of urinary incontinence
IL155433A0 (en) Treatment of t cell disorders
IL155174A0 (en) Methods and compositions for the treatment of inflammatory diseases
AU2002362115A1 (en) Composition and methods for treatment of neurological disorders
AU2002309180A1 (en) Composition and kit for the treatment of inflammatory bowel diseases
AU2002254174A1 (en) Interferon-beta polynucleotide therapy for autoimmune and inflammatory diseases
AUPQ968700A0 (en) Treatment of urinary incontinence
AU1953701A (en) Methods and compositions for treatment of inflammatory disease
AU2001234831A1 (en) Magnetoliposome composition for targeted treatment of biological tissue and associated methods